A Phase Ia Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of HW241045 Tablets Following a Single Dose in Healthy Subjects: A Single-center, Randomized, Double-blind, Placebo-controlled Study
Latest Information Update: 12 Mar 2026
At a glance
- Drugs HW 241045 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Hubei Biological Medicine Industrial Technology Institute
Most Recent Events
- 12 Mar 2026 New trial record